sur B.R.A.I.N. Biotechnology Research And Information Network AG (isin : DE0005203947)
BRAIN Biotech AG Secures Licensing Deal with Akribion Therapeutics
BRAIN Biotech AG, based in Zwingenberg, Germany, has entered an exclusive licensing agreement with Akribion Therapeutics GmbH. This agreement covers BRAIN's G-dase E® CRISPR-Cas genome editing technology, specifically for pharmaceutical applications. The potential financial gain for BRAIN includes up to EUR 92.3 million through milestone fees and royalties.
The deal is structured around Akribion's progress in clinical development and market performance. Outside of pharmaceuticals, BRAIN retains the rights to utilize G-dase E® technology in its core business areas. This agreement is pending customary closing conditions.
Akribion Therapeutics is independently owned and funded by venture capital. The transaction underscores the potential financial growth for BRAIN through strategic partnerships.
R. P.
Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de B.R.A.I.N. Biotechnology Research And Information Network AG